Head and Neck Carcinoma Clinical Trials & Research at Providence Medical Group

Head and neck cancers start in the tissues and organs of the head and neck and include cancers of the larynx (voice box), throat, lips, mouth, nose, and salivary glands. Most head and neck cancers are squamous cell carcinomas and begin in the moist tissues that line the mouth, nose and throat. Tobacco use, heavy alcohol use, and infection with the human papillomavirus (HPV) increase your risk of head and neck cancer.

Providence Medical Group is currently enrolling patients for the following head and neck carcinoma clinical trial:

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-689)

Treatment agent: Pembrolizumab + standard of care radiation therapy
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03765918

Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma(GS 5916​)

Treatment agent: Magrolimab + Pembrolizumab, or 5-FU, Cisplatin, Carboplatin, or Docetael
PI: Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04854499?term=NCT04854499&draw=2&rank=1
Gilead Sciences, Inc.

Our Providers

Our Locations